ADMA Biologics rises after FDA approves sixth plasma collection center
27/06/2022 12:57
** Shares of biotech co ADMA Biologics ADMA.O rise 4.6% to
$2.03 premarket
** Co receives U.S. FDA approval for its sixth plasma
collection facility (https://refini.tv/3u7cdI5)
** ADMA BioCenters facility is now FDA-licensed to collect
and introduce into interstate commerce human source plasma for
further manufacturing in U.S.
* Facility, located in South Carolina, commenced operations
and initiated source plasma collection in Q4 of 2021
** ADMA says it is on track to have all 10 plasma collection
centers FDA-approved by year-end 2023
** ADMA up ~38% so far in 2022
(Reporting by Mrinalika Roy in Bengaluru)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))